Rep. April McClain Delaney Sells Off STERIS plc (NYSE:STE) Stock

Representative April McClain Delaney (Democratic-Maryland) recently sold shares of STERIS plc (NYSE:STE). In a filing disclosed on August 03rd, the Representative disclosed that they had sold between $1,001 and $15,000 in STERIS stock on July 27th.

Representative April McClain Delaney also recently made the following trade(s):

• Purchased $15,001 – $50,000 in shares of Life Time Group (NYSE:LTH) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Liberty Media Corporation – Liberty Formula One Series C (NASDAQ:FWONK) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of C.H. Robinson Worldwide (NASDAQ:CHRW) on 7/31/2026.
• Sold $1,001 – $15,000 in shares of STERIS (NYSE:STE) on 7/31/2026.
• Purchased $15,001 – $50,000 in shares of Somnigroup International (NYSE:SGI) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Entegris (NASDAQ:ENTG) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Corpay (NYSE:CPAY) on 7/30/2026.
• Purchased $1,001 – $15,000 in shares of Life Time Group (NYSE:LTH) on 7/30/2026.
• Sold $1,001 – $15,000 in shares of Service Corporation International (NYSE:SCI) on 7/30/2026.

STERIS Stock Up 0.2%

Shares of NYSE:STE opened at $233.17 on Wednesday. The company has a debt-to-equity ratio of 0.25, a current ratio of 2.09 and a quick ratio of 1.54. The firm has a market capitalization of $22.72 billion, a PE ratio of 29.40 and a beta of 0.91. The firm’s 50-day moving average is $213.64 and its two-hundred day moving average is $225.91. STERIS plc has a 1 year low of $195.14 and a 1 year high of $269.44.

STERIS (NYSE:STE) last issued its quarterly earnings results on Monday, May 11th. The medical equipment provider reported $2.83 earnings per share (EPS) for the quarter, missing the consensus estimate of $2.86 by ($0.03). STERIS had a return on equity of 14.15% and a net margin of 13.18%.The business had revenue of $1.59 billion for the quarter, compared to analyst estimates of $1.59 billion. During the same period in the prior year, the company posted $2.74 EPS. The firm’s revenue for the quarter was up 6.7% compared to the same quarter last year. STERIS has set its FY 2027 guidance at 11.100-11.300 EPS. Analysts predict that STERIS plc will post 11.17 EPS for the current year.

STERIS Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, September 25th. Shareholders of record on Friday, September 4th will be paid a dividend of $0.69 per share. This represents a $2.76 dividend on an annualized basis and a yield of 1.2%. This is a boost from STERIS’s previous quarterly dividend of $0.63. The ex-dividend date is Friday, September 4th. STERIS’s payout ratio is currently 31.78%.

Analyst Upgrades and Downgrades

Several brokerages recently weighed in on STE. Weiss Ratings downgraded shares of STERIS from a “hold (c+)” rating to a “hold (c)” rating in a research note on Wednesday, May 27th. KeyCorp dropped their price target on shares of STERIS from $291.00 to $269.00 and set an “overweight” rating for the company in a research note on Wednesday, May 13th. Piper Sandler reaffirmed an “overweight” rating and set a $270.00 price objective on shares of STERIS in a research report on Thursday, May 21st. UBS Group started coverage on STERIS in a research note on Tuesday, July 28th. They issued a “buy” rating and a $275.00 price objective on the stock. Finally, Wall Street Zen lowered STERIS from a “buy” rating to a “hold” rating in a report on Saturday. Four research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the stock. According to MarketBeat.com, STERIS currently has an average rating of “Moderate Buy” and a consensus price target of $277.25.

Institutional Inflows and Outflows

Institutional investors have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its holdings in STERIS by 0.6% during the 4th quarter. Vanguard Group Inc. now owns 12,286,535 shares of the medical equipment provider’s stock worth $3,114,882,000 after acquiring an additional 73,014 shares in the last quarter. State Street Corp raised its holdings in shares of STERIS by 6.0% in the 4th quarter. State Street Corp now owns 4,614,840 shares of the medical equipment provider’s stock valued at $1,169,957,000 after purchasing an additional 260,001 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of STERIS by 0.6% in the 4th quarter. Geode Capital Management LLC now owns 2,523,620 shares of the medical equipment provider’s stock valued at $637,259,000 after purchasing an additional 14,151 shares in the last quarter. Orbis Allan Gray Ltd lifted its position in shares of STERIS by 5.6% during the 4th quarter. Orbis Allan Gray Ltd now owns 2,249,511 shares of the medical equipment provider’s stock worth $570,296,000 after purchasing an additional 120,200 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of STERIS by 25.7% during the first quarter. Janus Henderson Group PLC now owns 1,863,139 shares of the medical equipment provider’s stock worth $411,995,000 after purchasing an additional 380,504 shares in the last quarter. Hedge funds and other institutional investors own 94.69% of the company’s stock.

Insider Activity at STERIS

In related news, VP John Adam Zangerle sold 1,419 shares of the stock in a transaction on Monday, June 15th. The stock was sold at an average price of $209.28, for a total value of $296,968.32. Following the transaction, the vice president owned 35,259 shares of the company’s stock, valued at $7,379,003.52. This represents a 3.87% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Richard C. Breeden sold 1,481 shares of the firm’s stock in a transaction on Tuesday, June 2nd. The shares were sold at an average price of $209.51, for a total value of $310,284.31. Following the completion of the sale, the director owned 38,964 shares in the company, valued at approximately $8,163,347.64. This represents a 3.66% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 7,328 shares of company stock valued at $1,554,051 over the last quarter. 1.12% of the stock is owned by insiders.

About Representative McClain Delaney

April McClain-Delaney (Democratic Party) is a member of the U.S. House, representing Maryland’s 6th Congressional District. She assumed office on January 3, 2025. Her current term ends on January 3, 2027.

McClain-Delaney (Democratic Party) is running for re-election to the U.S. House to represent Maryland’s 6th Congressional District. She declared candidacy for the 2026 election.

April McClain-Delaney grew up in Buhl, Idaho, where her father was a potato farmer. She obtained her bachelor’s degree in communications from Northwestern University in 1986 and her law degree from Georgetown Law Center in 1989. McClain-Delaney worked in communications law, first with the satellite firm Orion Network Systems and later as the Washington director for Common Sense Media, a nonprofit focused on technology and children. In 2022, McClain-Delaney joined the U.S. Department of Commerce under President Joe Biden (D) as deputy assistant secretary for communications and information. McClain-Delaney served on the board of the Georgetown University Law Center, the International Center for Research on Women, and the Northwestern University School of Communications.

About STERIS

STERIS Corporation (NYSE: STE) is a global provider of infection prevention, contamination control and procedural products and services for the healthcare, life sciences, pharmaceutical and medical device industries. The company develops, manufactures and supports a broad portfolio of equipment and consumables designed to reduce risk of infection, maintain sterile environments and support critical clinical and manufacturing procedures.

Its offerings include sterilization and decontamination systems, instrument washers and washers-disinfectors, endoscope reprocessing solutions, surgical equipment and procedural disposables, and contamination-control products for cleanrooms and laboratories.